key: cord-0054495-domvoa2g authors: Prisco, Sasha Z.; Thenappan, Thenappan; Prins, Kurt W. title: Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension date: 2020-12-28 journal: JACC Basic Transl Sci DOI: 10.1016/j.jacbts.2020.07.011 sha: 0de455689f9fe841060cb31378c7e2150fd3be5b doc_id: 54495 cord_uid: domvoa2g Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease. , and the response of the RV to PAHspecific therapy determines survival (4, 5) . Moreover, RV dysfunction is not solely caused by increased afterload, as some PAH patients exhibit progression of RV dysfunction despite treatment with pulmonary vasodilators (6, 7) . Furthermore, patients with systemic sclerosis-associated PAH (SSc-PAH) have worse RV function-and consequently increased mortality-compared with patients who have idiopathic PAH (IPAH), despite having similar severity of pulmonary vascular disease (6, 8) . Unfortunately, no currently available PAH therapy directly targets the RV. Therefore, there is an unmet need to combat the mechanisms underlying RV dysfunction directly to improve long-term outcomes in PAH. In addition to PAH, RV dysfunction is prognostic in the 2 leading causes of pulmonary hypertension (PH): PH caused by left heart disease (World Health Organization [WHO] Group 2) and lung disease (WHO Group 3) (9) (10) (11) . RV function predicts mortality (12, 13) and is affected independent of afterload in Group 2 PH (14) . Despite having less severe pulmonary vascular disease than patients with PAH, Group 3 PH patients have disproportionate RV dysfunction and poor survival (15) . The presence of RV dysfunction in Group 3 PH also identifies patients at high risk of poor outcomes (11, 16) . Unfortunately, PAH-specific therapies do not significantly improve exercise capacity or reduce symptom burden in Group 2 and 3 PH (17) . Thus, RV-directed therapy may be beneficial for these prevalent and currently untreatable causes of PH. Mechanistic dissections of RV dysfunction have lagged behind our understanding of left ventricular (LV) dysfunction. This is exemplified by the fact that there are multiple therapies with proven survival benefits for LV failure (18, 19) but no approved drugs for RV dysfunction. Importantly, the use of standard therapies for LV failure, such as beta blockers and targets of the renin-angiotensin-aldosterone system (RAAS), are not indicated or potentially contraindicated in patients with PAH and RV dysfunction (20, 21) . Thus, understanding the differences between the RV and LV may be important to define RV-directed therapies ( Figure 1 , Table 1 ). There are developmental, anatomic, and functional differences between the RV and LV ( Figure 1 ) that may provide insight into ways to enhance ventriclespecific function ( Figure 2 , Table 1 ). Developmentally, the LV originates first from the splanchnic mesoderm within the primary heart field (22) , whereas the RV develops second from the extracardiac mesoderm within the secondary heart field (23) . The prenatal RV is thick walled and generates high pressures to support fetal blood flow (24) . After birth, the pulmonary circulation becomes a low pressure circuit (25), whereas the systemic circulation becomes a high pressure system, which leads to relative LV hypertrophy (26) . Ultimately, the RV becomes a thin-walled, crescent-shaped chamber, whereas the LV takes a muscular bullet shape (27) . Furthermore, there are dissimilarities in cardiomyocyte arrangement that lead to differences in contractility between the 2 ventricles. The adult RV has 2 layers of cardiomyocytes: a circumferential layer that brings the RV free wall toward the interventricular septum and a deeper layer of vertical fibers that result in longitudinal shortening, which accounts for 75% of the total RV contractility (28). In contrast, the LV has 3 myocardial layers. LV contraction is a function of radial fiber thickening, longitudinal fiber shortening, and oblique fiber thickening (29) . Circumferential and longitudinal shortening contribute to 67% and 33% of total LV contractility, respectively (30) . Moreover, there are differences in ventricular perfusion, as the RV is perfused throughout the cardiac cycle, whereas the LV is only perfused during diastole (31) . Although the normal RV and LV have similar coronary flow reserves of 400% to 500% (32) (33) (34) (35) , the RV has lower baseline oxygen consumption and greater oxygen extraction reserve, which lowers its risk of ischemic injury caused by decreased coronary flow (31) . However, the pressure-overloaded RV is more susceptible to ischemia, with acute or chronic increases in afterload as elevated RV afterload reduces the systolic RV perfusion gradient. This curtails overall RV perfusion because the RV is normally perfused during both systole and diastole (31) . Finally, there are important anatomic differences between the ventricles that alter their response to preload and afterload. The RV is thinner and has lower volume to wall surface area, which makes the RV more compliant and better adapted to initial volume increases but renders it unable to accommodate afterload increases as well as the LV (36). This is supported by a study of isolated rat hearts that shows the LV has a higher afterload reserve than the RV (37) . There are divergent molecular responses between RV and LV failure documented in animal and human studies (27, 38, 39) . In brief, there are differences in adrenergic signaling regulation as b1and a1-adenergic and dopamine-1 receptors are downregulated in the pressure overloaded RV, which leads to a diminished inotropic response (38, 39) . Although there is also downregulation of b1-adenergic receptors in LV dysfunction (40) , a1-adrenergic receptors are actually upregulated and increase contractility in the pressure overloaded LV (27, 38, 39, 41) . Conversely, a1-receptor signaling decreases inotropy in the overloaded RV (27, 38, 39) . Furthermore, there are dissimilarities in the response to catecholamines, as only the LV develops hypertrophy following norepinephrine infusion (27, 38) . EXPERIMENTAL MODELS OF PAH. Several commonly used preclinical models of PAH are discussed in the following sections. (79) . We also showed t-tubule disarray and downregulation of junctophilin-2 in the monocrotaline RV (80) . Colchicine treatment to combat pathological microtubule remodeling increases junctophilin-2, partially corrects t-tubule architecture, and improves RV function in monocrotaline rats, albeit in the setting of less severe pulmonary vascular remodeling (80) . These data suggest that t-tubule remodeling promotes RV dysfunction, but both At baseline, RV has higher collagen content (75) and different expression of matrix metalloproteinases and extracellular matrix proteins (76) compared with the LV. Antifibrotic therapies that are effective in the LV (pirfenidone and eplerenone) do not reverse fibrosis in the RV (57, 72) . Inflammation RV has more macrophages and dendritic cells at baseline compared with the LV (95) . Estrogen signaling In the dysfunctional RV, the beneficial effects of estrogen are predominately mediated by ER-a (98), but in LV pressure overload, stimulation of ER-b normalizes LV ejection fraction (106) . Ischemia RV is perfused during both systole and diastole, whereas the LV is only perfused during diastole (31) . At baseline, RV has a reduced microvascular bed with less tissue perfusion compared with the LV (135). There may be decreased angiogenesis during RV failure (110, (121) (122) (123) . There are baseline differences in miRNA expression between the RV and LV (140) . RV-specific miRNAs that are dysregulated during RV dysfunction: miR-21, -28, -34a, -93, -126/VEGF, -127, -130a, -146b, -148a, -197, -208/ Mef2c, -221, and let-7e (39, 133, (140) (141) (142) (143) 145) . studies have the caveat of reduced PAH severity (79, 80) . Nonetheless, strategies to normalize junctophilin-2 levels and restore t-tubule architecture may enhance RV function. SARCOMERIC ABNORMALITIES. There is emerging evidence that altered sarcomere function promotes RV dysfunction in PAH. In pulmonary artery-banded rats, RV myocardial stiffness is observed in both mild and severe dysfunction (62 expression, leading to more severe heart failure following pressure overload in mice (86) . Importantly, this phenotype is reversed by either upregulation of regnase-1 expression or administration of an anti-IL-6 receptor antibody (86) . Clearly, there is evidence that inflammation negatively affects cardiac function. Prisco et al. Clinical trials investigating the effects of antagonizing IL-1 (anakinra), IL-6 (tocilizumab), and CD20 on B cells (rituximab) in PAH are completed ( Table 3) . Larger trials may be needed to determine the utility of FAO inhibitors in RV dysfunction in PAH. Prisco et al. Recruiting *Some of the trials that are active but not currently recruiting as of May 2020 may be due to the current COVID-19 pandemic. †Trial in patients with severe functional regurgitation. CMR ¼ cardiovascular magnetic resonance imaging; CPET ¼ cardiopulmonary exercise testing; DHEA ¼ dehydroepiandrosterone; Ees ¼ end-systolic elastance; FDG-PET ¼ fluorodeoxyglucose-positron emission tomography; NT-proBNP ¼ N-terminal-pro-brain natriuretic peptide; PVR ¼ pulmonary vascular resistance; RHC ¼ right heart catheterization; RV ¼ right ventricle; RVEF ¼ right ventricular ejection fraction; TAPSE ¼ tricuspid annular plane systolic excursion; WHO ¼ World Health Organization. Prisco et al. heightens RV contractility in isolated rodent hearts (165) . The beneficial effects of PDE5 inhibitors on the RV and exercise capacity are also supported by a randomized controlled trial that investigated the effects of sildenafil (a PDE5 inhibitor) therapy on exercise performance in patients with PH due to LV systolic function (166) . In this trial, sildenafil treatment heightened maximal volume of oxygen consumption, exercise cardiac output, and RV ejection fraction at rest and at peak exercise (166) . However, the significant reduction in pulmonary vascular resistance needs to be considered when interpreting the change in RV function with sildenafil therapy in these patients. Certainly, further research is needed to understand the mechanisms by which exercise improves RV function in PAH and other PH subgroups. Several ongoing clinical trials are investigating the role of exercise on RV function ( Table 3) ; it is hoped that they will provide more insight moving forward. Multiple clinical trials have investigated or are currently investigating the targets of RV dysfunction discussed in this review (Table 3) . However, majority of these clinical trials are not specifically investigating RV function as a primary outcome. There are some encouraging preliminary findings, as carvedilol enhances RV function (167) and decreases RV glucose uptake (168) . In addition, ranolazine (118) and trimetazidine show trends for improvement in RV function. It is hoped that 1 or more of these trials will identify targets for RV failure to improve outcomes in patients with PAH and, eventually, patients with PH due to other causes. RV dysfunction is the strongest predictor of mortality in PAH (1-3), but none of the currently available PAH therapies directly target the failing RV. Here, we discussed the known molecular mechanisms involved in RV dysfunction in PAH to delineate potential targets for RV-enhancing or RV-directed therapies (Central Illustration). Furthermore, we highlighted the important differences between the RV and LV, which may be particularly relevant for developing RVdirected therapies. Finally, we summarized recent and ongoing clinical trials targeting the molecular mechanisms of RV dysfunction in PAH. We hope that ongoing and future studies will identify RV-targeted therapies that will enhance quality of life and improve survival in PAH. ACKNOWLEDGMENT The authors thank Cynthia Faraday for her assistance with designing the figures. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension Right ventricular dysfunction in systemic sclerosisassociated pulmonary arterial hypertension Differences in right ventricular functional changes during treatment between systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension Right ventricular functional reserve in pulmonary arterial hypertension Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort Aetiology and outcomes of severe right ventricular dysfunction Right ventricular function in heart failure with preserved ejection fraction: a communitybased study Right heart dysfunction in heart failure with preserved ejection fraction Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and metaanalysis ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study Captopril in primary pulmonary hypertension Signal transduction in early heart development (II): ventricular chamber specification, trabeculation, and heart valve formation The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field Quantitative assessment of right and left ventricular growth in the human fetal heart: a pathoanatomic study Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. I. Hypertrophy, hyperplasia, and binucleation of myocytes Longitudinal shortening accounts for the majority of right ventricular contraction and improves after pulmonary vasodilator therapy in normal subjects and patients with pulmonary arterial hypertension How does the left ventricle work? Ventricular rotation as a new index of cardiac performance The relative impact of circumferential and longitudinal shortening on left ventricular ejection fraction and stroke volume Right Ventricular perfusion: physiology and clinical implications Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans Right and left ventricular oxygen metabolism in open-chest dogs Right and left ventricular O2 uptake during hemodilution and beta-adrenergic stimulation Alpha-adrenergic vasoconstrictor tone limits right coronary blood flow in exercising dogs Biomechanics of the right ventricle in health and disease Comparison between left and right heart function in the isolated biventricular working rat heart Right ventricular phenotype, function, and failure: a journey from evolution to clinics Molecular mechanisms of right ventricular failure New insights in cardiac b-adrenergic signaling during heart failure and aging Cardiac alpha 1-adrenergic drive in pathological remodelling Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives The angiotensin-converting enzyme 2/angiogenesis Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotalineinduced right ventricular hypertrophy in rats Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics A potential therapeutic role for angiotensinconverting enzyme 2 in human pulmonary arterial hypertension Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension: relative contribution of fibrosis and myofibril stiffness Right ventricular diastolic impairment in patients with pulmonary arterial hypertension Impairment of Excitation-contraction coupling in right ventricular hypertrophied muscle with fibrosis induced by pulmonary artery banding Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-b1 signaling and is abrogated by angiotensin receptor blockade A selective transforming growth factor-b ligand trap attenuates pulmonary hypertension 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of PA de-banding Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A Quantitation of collagen in human myocardium Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies The structure and function of cardiac t-tubules in health and disease Junctophilins: a novel family of junctional membrane complex proteins Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2þ) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension Colchicine depolymerizes microtubules, increases junctophilin-2, and improves right ventricular function in experimental pulmonary arterial hypertension Right ventricular myofilament functional differences in humans with systemic sclerosisassociated versus idiopathic pulmonary arterial hypertension Inflammation in pulmonary arterial hypertension Inflammation, growth factors, and pulmonary vascular remodeling Deletion of interleukin-6 attenuates pressure overloadinduced left ventricular hypertrophy and dysfunction Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca Cytokine mRNA degradation in cardiomyocytes restrains sterile inflammation in pressure-overloaded hearts Inflammatory mediators drive adverse right ventricular remodeling and dysfunction and serve as potential biomarkers Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension Increased levels of plasma CXC-chemokine ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension Early inflammatory response during the development of right ventricular heart failure in a rat model Long-term pressureinduced cardiac hypertrophy: capillary and mast cell proliferation Opposite effects of training in rats with stable and progressive pulmonary hypertension Activation of apoptotic pathways in experimental acute afterload-induced right ventricular failure Exercise preconditioning prevents MCT-induced right ventricle remodeling through the regulation of TNF superfamily cytokines Transcriptomic profiles reveal differences between the right and left ventricle in normoxia and hypoxia IL-1 Blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB/II pilot study Sex, gender, and sex hormones in pulmonary hypertension and right ventricular failure Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Determinants of right ventricular ejection fraction in pulmonary arterial hypertension Estrogen rescues heart failure through estrogen receptor beta activation Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle PPARg agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study Right coronary artery flow impairment in patients with pulmonary hypertension Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension Vascular adaptation of the right ventricle in experimental pulmonary hypertension Right ventricle vasculature in human pulmonary hypertension assessed by stereology Angiogenesis in skeletal and cardiac muscle HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease Molecular mechanisms of hypoxiainducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart Hypoxiainducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse Molecular signature of a right heart failure program in chronic severe pulmonary hypertension Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension Supracoronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion Microvascular development in porcine right and left ventricular walls Mechanisms of oxygen demand/supply balance in the right ventricle Advances in epigenetics link genetics to the environment and disease The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials The emerging role of epigenetics in pulmonary hypertension Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure Differential microRNA-21 and microRNA-221 upregulation in the biventricular failing heart reveals distinct stress responses of right versus left ventricular fibroblasts Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle Identification of the long non-coding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension Histone acetylation and deacetylation Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism Alterations in cardiac DNA methylation in human dilated cardiomyopathy Distinct epigenomic features in end-stage failing human hearts Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension: a pyruvate dehydrogenase kinasedependent shift in mitochondrial metabolism promotes right ventricular fibrosis Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues Regulation of murine cardiac 20S proteasomes: role of associating partners Twodimensional electrophoresis-based characterization of post-translational modifications of mammalian 20S proteasome complexes Altered proteasome function in right ventricular hypertrophy Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure Proteomic remodeling of proteasome in right heart failure Pathophysiology of exercise intolerance in pulmonary arterial hypertension Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis High-intensity interval training, but not continuous training, reverses right ventricular hypertrophy and dysfunction in a rat model of pulmonary hypertension Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Treatment of group I pulmonary arterial hypertension with carvedilol is safe Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial Experimental models of right heart failure: a window for translational research in pulmonary hypertension Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure Anastrozole in pulmonary arterial hypertension: a randomized, double-blind, placebocontrolled trial Phase I safety study of ranolazine in pulmonary arterial hypertension Rationale and design of the ranolazine PH-RV study: a multicentered randomised and placebo-controlled study of ranolazine to improve RV function in patients with nongroup 2 pulmonary hypertension